Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 11/20 | 1.00 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.36 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.36 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6943973 | 1.00 | SRD5A1 (1.00) | SRD5A1NOTUMESR1CHRM2CHRM4 | |
| SCHEMBL6945939 | 1.00 | SRD5A1 (1.00) | SRD5A1NOTUMESR1CHRM2CHRM4 | |
| SCHEMBL7052742 | 1.00 | SRD5A1 (1.00) | SRD5A1NOTUMESR1CHRM2CHRM4 | |
| SCHEMBL7050013 | 0.82 | SRD5A1 (1.00) | SRD5A1NOTUM | |
| SCHEMBL6945153 | 0.82 | SRD5A1 (1.00) | SRD5A1NOTUM | |
| SCHEMBL7051403 | 0.81 | SRD5A1 (1.00) | SRD5A1NOTUMHSD17B3 | |
| SCHEMBL6944630 | 0.81 | SRD5A1 (1.00) | SRD5A1NOTUMHSD17B3 | |
| SCHEMBL6940070 | 0.70 | SRD5A1 (1.00) | SRD5A1NOTUM | |
| SCHEMBL6946528 | 0.69 | SRD5A1 (0.52) | SRD5A1ESR1CHRM2CHRM4CHRM1 | |
| SCHEMBL25444808 | 0.64 | SRD5A1 (0.47) | SRD5A1CHRM2CHRM4CHRM1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6552034-B2 | Cyclization of a silylated butadiene reacted with a 2-oxo-1,2,3,4-tetrahydroquinoline; acne; alopecia; prostatic cancer and hypertrophy; hirsutism in women; skin and glandular disorders; anticarcinogenic agents | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2003-04-22 | — | — | US | disclosed |
| EP-0880520-B1 | BENZO [C]QUINOLIZINE DERIVATIVES, THEIR PREPARATION AND USE AS 5-ALPHA-REDUCTASES INHIBITORS | APPLIED RESEARCH SYSTEMS (AN) | 2003-04-16 | — | — | EP | disclosed |
| US-20010047098-A1 | Benzo[c]quinolizine derivatives, their preparation and use as 5alpha-reductases inhibitors | MERCK SERONO SA (CH) | 2001-11-29 | — | — | US | disclosed |
| US-20010044542-A1 | Benzo [c] quinolizine derivatives, their preparation and use as 5alpha-reductases inhibitors | MERCK SERONO SA (CH) | 2001-11-22 | — | — | US | disclosed |
| US-6303622-B1 | FOR THERAPY OF ACNE, BALDNESS, PROSTATE CANCER, PROSTATIC HYPERTROPHY; HIRSUTISM | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2001-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010044542-A1 | Benzo [c] quinolizine derivatives, their preparation and use as 5alpha-reductases inhibitors | CYP3A5, CYP51A1, CYP2F1 | SRD5A1 8/4885NOTUM 551/4885ESR1 1434/4885 |
| US-20010047098-A1 | Benzo[c]quinolizine derivatives, their preparation and use as 5alpha-reductases inhibitors | CYP3A5, CYP51A1, CYP2F1 | SRD5A1 8/4885NOTUM 551/4885ESR1 1434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.